JP2014501768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501768A5 JP2014501768A5 JP2013547850A JP2013547850A JP2014501768A5 JP 2014501768 A5 JP2014501768 A5 JP 2014501768A5 JP 2013547850 A JP2013547850 A JP 2013547850A JP 2013547850 A JP2013547850 A JP 2013547850A JP 2014501768 A5 JP2014501768 A5 JP 2014501768A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- liposome
- liposome preparation
- suspension
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 3
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 claims description 3
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 3
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims description 2
- 101150079015 esxB gene Proteins 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000000725 suspension Substances 0.000 claims 13
- 238000009472 formulation Methods 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 10
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 238000001962 electrophoresis Methods 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 201000008827 tuberculosis Diseases 0.000 claims 5
- 229920002401 polyacrylamide Polymers 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 206010065048 Latent tuberculosis Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 229960000885 rifabutin Drugs 0.000 claims 2
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000036981 active tuberculosis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 229940099352 cholate Drugs 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229940107161 cholesterol Drugs 0.000 claims 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical group C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 229940009976 deoxycholate Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 229960003350 isoniazid Drugs 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 208000033353 latent tuberculosis infection Diseases 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 230000009862 primary prevention Effects 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11150072.4 | 2011-01-04 | ||
| EP11150072A EP2471511A1 (en) | 2011-01-04 | 2011-01-04 | Liposome formulation suitable for treating or preventing tuberculosis |
| EP11183487 | 2011-09-30 | ||
| EP11183487.5 | 2011-09-30 | ||
| PCT/EP2012/050080 WO2012093137A1 (en) | 2011-01-04 | 2012-01-04 | Liposome formulation suitable for treating or preventing tuberculosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014501768A JP2014501768A (ja) | 2014-01-23 |
| JP2014501768A5 true JP2014501768A5 (enExample) | 2015-02-19 |
| JP6096675B2 JP6096675B2 (ja) | 2017-03-15 |
Family
ID=45509459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547850A Active JP6096675B2 (ja) | 2011-01-04 | 2012-01-04 | 結核の治療又は予防に適切なリポソーム製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9877917B2 (enExample) |
| EP (1) | EP2661253B1 (enExample) |
| JP (1) | JP6096675B2 (enExample) |
| KR (1) | KR101820026B1 (enExample) |
| CN (2) | CN103796640A (enExample) |
| BR (1) | BR112013017267B1 (enExample) |
| CA (1) | CA2823747C (enExample) |
| CO (1) | CO6801728A2 (enExample) |
| ES (1) | ES2631556T3 (enExample) |
| HU (1) | HUE032409T2 (enExample) |
| IL (1) | IL227338B (enExample) |
| LT (1) | LT2661253T (enExample) |
| MX (1) | MX341918B (enExample) |
| PL (1) | PL2661253T3 (enExample) |
| RU (1) | RU2648842C2 (enExample) |
| SI (1) | SI2661253T1 (enExample) |
| WO (1) | WO2012093137A1 (enExample) |
| ZA (1) | ZA201305697B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103720657B (zh) * | 2013-11-19 | 2017-01-04 | 广东丸美生物技术股份有限公司 | 一种可变形脂质体的制备方法，及其制备的可变性脂质体 |
| JP2016163851A (ja) * | 2015-03-06 | 2016-09-08 | 国立大学法人福井大学 | コンポジット型可溶化ナノリポソーム及びその製造方法 |
| RU2631607C1 (ru) * | 2016-11-22 | 2017-09-25 | Владислав Николаевич Ласкавый | Средство для профилактики лейкоза крупного рогатого скота и способ его применения |
| GB201707700D0 (en) * | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| CN109675059A (zh) * | 2019-01-23 | 2019-04-26 | 青岛大学 | 一种类杆菌脂质体及其制备方法与应用 |
| US11202823B2 (en) * | 2019-04-05 | 2021-12-21 | Northwestern University | Multi-subunit vaccines to elicit both MHC- and CD1-restricted T cell responses |
| CN120456894A (zh) * | 2021-10-14 | 2025-08-08 | 爱琴韦尔制药公司 | 用于治疗活动性结核病的脂质体制剂 |
| CN115850520A (zh) * | 2022-12-12 | 2023-03-28 | 中国农业大学 | 新型结核病亚单位疫苗al的制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9900378A3 (en) * | 1995-02-22 | 1999-11-29 | Adcock Ingram Ltd | A method for the isolation and purification of lipid cell-wall components |
| GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US7393540B2 (en) | 2001-07-04 | 2008-07-01 | Health Protection Agency | Mycobacterial antigens expressed during latency |
| BR0103887C1 (pt) * | 2001-07-17 | 2005-11-08 | Univ Minas Gerais | Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes |
| ES2231037B1 (es) | 2003-10-31 | 2005-12-16 | Archivel Technologies, Sl | Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos. |
| EP1761662A4 (en) | 2004-07-01 | 2010-02-03 | Univ California | PROTEOMICS WITH HIGH THROUGHPUT |
| PT2426141E (pt) * | 2005-04-29 | 2014-11-25 | Glaxosmithkline Biolog Sa | Método para prevenção ou tratamento de uma infecção por m. tuberculosis |
| CN101283085A (zh) * | 2005-08-11 | 2008-10-08 | 哈佛大学的校长及成员们 | 用于干燥细胞形式的方法和组合物 |
| WO2007022152A2 (en) | 2005-08-15 | 2007-02-22 | The Research Foundation Of State University Of New York | Lipid nano particulates containing antigens as cancer vaccines |
| US9393215B2 (en) * | 2005-12-02 | 2016-07-19 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| US20090081284A1 (en) | 2006-04-20 | 2009-03-26 | Tokai University Educational System | Therapeutic agent for allergy containing liposome having oligosaccharide on its surface |
| HUE031951T2 (en) | 2006-10-10 | 2017-08-28 | Jina Pharmaceuticals Inc | Aqueous systems for lipid-based drug compounds; preparations, processes and their use |
| ES2307402B1 (es) | 2006-10-30 | 2009-09-30 | Archivel Farma, S.L. | Vacuna profilactica contra la tuberculosis. |
| BRPI0705630F8 (pt) * | 2007-12-12 | 2022-01-18 | Univ Estadual Campinas Unicamp | Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma |
| CN101969976A (zh) | 2008-01-11 | 2011-02-09 | 美国政府健康与人类服务部秘书处 | 针对分枝杆菌的多肽疫苗和接种策略 |
| ES2335177B1 (es) | 2008-09-19 | 2011-02-28 | Archivel Farma, S.L. | Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis. |
| EP2421557B1 (en) * | 2009-04-24 | 2018-12-05 | Statens Serum Institut | A tuberculosis tb vaccine to prevent reactivation |
| SG190937A1 (en) * | 2010-12-14 | 2013-07-31 | Glaxosmithkline Biolog Sa | Mycobacterium antigenic composition |
-
2012
- 2012-01-04 BR BR112013017267-3A patent/BR112013017267B1/pt active IP Right Grant
- 2012-01-04 RU RU2013136379A patent/RU2648842C2/ru active
- 2012-01-04 CN CN201280011787.0A patent/CN103796640A/zh active Pending
- 2012-01-04 EP EP12700624.5A patent/EP2661253B1/en active Active
- 2012-01-04 WO PCT/EP2012/050080 patent/WO2012093137A1/en not_active Ceased
- 2012-01-04 SI SI201230956A patent/SI2661253T1/sl unknown
- 2012-01-04 HU HUE12700624A patent/HUE032409T2/en unknown
- 2012-01-04 JP JP2013547850A patent/JP6096675B2/ja active Active
- 2012-01-04 CN CN201710129725.4A patent/CN107296793A/zh active Pending
- 2012-01-04 LT LTEP12700624.5T patent/LT2661253T/lt unknown
- 2012-01-04 US US13/978,001 patent/US9877917B2/en active Active
- 2012-01-04 CA CA2823747A patent/CA2823747C/en active Active
- 2012-01-04 KR KR1020137020385A patent/KR101820026B1/ko active Active
- 2012-01-04 MX MX2013007855A patent/MX341918B/es active IP Right Grant
- 2012-01-04 ES ES12700624.5T patent/ES2631556T3/es active Active
- 2012-01-04 PL PL12700624T patent/PL2661253T3/pl unknown
-
2013
- 2013-07-04 CO CO13158421A patent/CO6801728A2/es unknown
- 2013-07-04 IL IL227338A patent/IL227338B/en active IP Right Grant
- 2013-07-26 ZA ZA2013/05697A patent/ZA201305697B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abdelbary et al. | Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride | |
| RU2013136379A (ru) | Липосомный препарат, предназначенный для лечения или предупреждения туберкулеза | |
| AU2018201772A1 (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| El Temsahy et al. | The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice | |
| JP5713672B2 (ja) | 結核のワクチンおよびその使用方法 | |
| Tramont | Syphilis in adults: from Christopher Columbus to Sir Alexander Fleming to AIDS | |
| MXPA06006650A (es) | Composiciones farmaceuticas antivirales. | |
| ES2853773T3 (es) | Procedimientos novedosos para inducir una respuesta inmune | |
| WO2024093813A1 (zh) | 核苷类化合物的制药用途 | |
| ES2335177B1 (es) | Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis. | |
| MX2013002989A (es) | Micobacteria recombinante como vacuna para uso en humanos. | |
| RU2014133042A (ru) | Вакцина мбтк против астмы | |
| US9974847B2 (en) | Treatment and prevention of tuberculosis | |
| US20100278903A1 (en) | Prophylactic and immunomodulatory compositions and uses | |
| Germani et al. | Emergence of cholera in the Central African Republic | |
| Basyony et al. | Antimicrobial susceptibility profile, Adherence and invasion to mammalian cells of Brucella melitensis isolates. | |
| RU2850217C1 (ru) | Назальный спрей, применяемый при лечении коронавирусной инфекции | |
| Gupta et al. | Primary mucocutaneous tuberculosis of nose: one decade study | |
| Freixeiro et al. | Solid sorbitan esters nanoparticles are efficient and low-cost vehicles for subunit vaccines: Proof of concept with Neisseria meningitidis protein Mip | |
| US20230111350A1 (en) | Opthalmic Compositions for Treating Coronaviruses | |
| Mejías et al. | Killing it softly–Can soft materials play a strategic role in the eradication of tuberculosis? | |
| Sedaghat et al. | Determination of bactericidal activity of serum against Vibrio cholerae outer membrane vesicles in BALB/c mice | |
| Germani et al. | Central African Republic | |
| SYPHIUS-byyear | meO'r>< 1Phlll | |
| US20150320849A1 (en) | Method of treating central nervous system disorders with Borrelia burgdorferi antigen |